Mammalian target of rapamycin (mTOR) inhibitors: potential uses and a review of haematological adverse effects (Q33393707)

26 July 2017

title

Mammalian target of rapamycin (mTOR) inhibitors: potential uses and a review of haematological adverse effects (English)

1 reference

26 July 2017

1 reference

2

David Goldsmith

1 reference

26 July 2017

Sofia Sofroniadou

1

1 reference

26 July 2017

publication date

1 February 2011

1 reference

26 July 2017

1 reference

26 July 2017

volume

34

1 reference

26 July 2017

issue

2

1 reference

26 July 2017

page(s)

97-115

1 reference

Regulation of translation initiation by FRAP/mTOR

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.2165/11585040-000000000-00000

Tor signalling in bugs, brain and brawn

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11585040-000000000-00000

Insulin and amino-acid regulation of mTOR signaling and kinase activity through the Rheb GTPase

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11585040-000000000-00000

TOR signaling in growth and metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11585040-000000000-00000

21 January 2018

Expanding mTOR signaling

1 reference

https://api.crossref.org/works/10.2165/11585040-000000000-00000

mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11585040-000000000-00000

Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11585040-000000000-00000

PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11585040-000000000-00000

Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11585040-000000000-00000

Identification of Protor as a novel Rictor-binding component of mTOR complex-2

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11585040-000000000-00000

Growing roles for the mTOR pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11585040-000000000-00000

Sirolimus: a new promising immunosuppressive drug. Towards a rationale for its use in renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11585040-000000000-00000

Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11585040-000000000-00000

Current development of mTOR inhibitors as anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11585040-000000000-00000

The rapamycin-sensitive signal transduction pathway as a target for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11585040-000000000-00000

Targeting the molecular target of rapamycin (mTOR).

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11585040-000000000-00000

Immunosuppressive effects and safety of a sirolimus/cyclosporine combination regimen for renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11585040-000000000-00000

Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11585040-000000000-00000

Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11585040-000000000-00000

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11585040-000000000-00000

Orthotopic liver transplantation using low-dose tacrolimus and sirolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11585040-000000000-00000

Liver transplantation using sirolimus and minimal corticosteroids (3-day taper).

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11585040-000000000-00000

Mycophenolate mofetil and sirolimus as calcineurin inhibitor-free immunosuppression for late cardiac-transplant recipients with chronic renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11585040-000000000-00000

Successful use in lung transplantation of an immunosuppressive regimen aimed at reducing target blood levels of sirolimus and tacrolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11585040-000000000-00000

Recovery of chronic renal impairment with sirolimus after lung transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11585040-000000000-00000

Sirolimus (rapamycin) for the treatment of steroid-refractory acute graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11585040-000000000-00000

Sirolimus for Kaposi's sarcoma in renal-transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11585040-000000000-00000

Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11585040-000000000-00000

Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11585040-000000000-00000

Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11585040-000000000-00000

Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11585040-000000000-00000

The immunosuppressive macrolide RAD inhibits growth of human Epstein-Barr virus-transformed B lymphocytes in vitro and in vivo: A potential approach to prevention and treatment of posttransplant lymphoproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11585040-000000000-00000

A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11585040-000000000-00000

Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11585040-000000000-00000

Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11585040-000000000-00000

Efficacy of a rapamycin analog (CCI-779) and IFN-gamma in tuberous sclerosis mouse models

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11585040-000000000-00000

Efficacy of rapamycin in patient with juvenile rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11585040-000000000-00000

Everolimus in patients with rheumatoid arthritis receiving concomitant methotrexate: a 3-month, double-blind, randomised, placebo-controlled, parallel-group, proof-of-concept study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11585040-000000000-00000

Rapamycin reduces disease activity and normalizes T cell activation-induced calcium fluxing in patients with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11585040-000000000-00000

Treatment with sirolimus results in complete responses in patients with autoimmune lymphoproliferative syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11585040-000000000-00000

Rapamycin ameliorates experimental autoimmune myocarditis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11585040-000000000-00000

Rapamycin successfully treats post-transplant autoimmune hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11585040-000000000-00000

Rapamycin ameliorates proteinuria-associated tubulointerstitial inflammation and fibrosis in experimental membranous nephropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11585040-000000000-00000

Rapamycin causes down-regulation of CCR5 and accumulation of anti-HIV beta-chemokines: an approach to suppress R5 strains of HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11585040-000000000-00000

A rational mechanism for combination treatment of Huntington's disease using lithium and rapamycin.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11585040-000000000-00000

The mTOR pathway is highly activated in diabetic nephropathy and rapamycin has a strong therapeutic potential.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11585040-000000000-00000

Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11585040-000000000-00000

Obesity increases vascular senescence and susceptibility to ischemic injury through chronic activation of Akt and mTOR.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11585040-000000000-00000

Safety and tolerability of sirolimus treatment in patients with autosomal dominant polycystic kidney disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11585040-000000000-00000

The rapamycin analogue SDZ RAD attenuates bleomycin-induced pulmonary fibrosis in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11585040-000000000-00000

Long-term treatment of bile duct-ligated rats with rapamycin (sirolimus) significantly attenuates liver fibrosis: analysis of the underlying mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11585040-000000000-00000

Rapamycin attenuates load-induced cardiac hypertrophy in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11585040-000000000-00000

Sirolimus-Eluting Stents versus Standard Stents in Patients with Stenosis in a Native Coronary Artery

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11585040-000000000-00000

A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11585040-000000000-00000

Ten years of sirolimus therapy in orthotopic liver transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11585040-000000000-00000

Human brain tumor xenografts in nude mice as a chemotherapy model

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11585040-000000000-00000

Comparison of everolimus-eluting and paclitaxel-eluting coronary stents in patients with two treated vessels: 2-year results from the SPIRIT III randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11585040-000000000-00000

Comparison of zotarolimus-eluting stents with sirolimus- and paclitaxel-eluting stents for coronary revascularization: the ZEST (comparison of the efficacy and safety of zotarolimus-eluting stent with sirolimus-eluting and paclitaxel-eluting stent f

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11585040-000000000-00000

Sirolimus-induced thrombocytopenia and leukopenia in renal transplant recipients: risk factors, incidence, progression, and management

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11585040-000000000-00000

Enhancement of human platelet aggregation and secretion induced by rapamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11585040-000000000-00000

Molecular cloning of a cDNA encoding interleukin 11, a stromal cell-derived lymphopoietic and hematopoietic cytokine

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11585040-000000000-00000

Phase I pharmacokinetic and pharmacodynamic study of weekly 1-hour and 24-hour infusion BMS-214662, a farnesyltransferase inhibitor, in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11585040-000000000-00000

Prevalence and management of anemia in renal transplant recipients: a European survey.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11585040-000000000-00000

Posttransplantation anemia in adult renal allograft recipients: prevalence and predictors

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11585040-000000000-00000

Anemia after renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11585040-000000000-00000

A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11585040-000000000-00000

Comparative effects of sirolimus and mycophenolate mofetil on erythropoiesis in kidney transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11585040-000000000-00000

Complete avoidance of calcineurin inhibitors in renal transplantation: a randomized trial comparing sirolimus and tacrolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11585040-000000000-00000

Reduced exposure to calcineurin inhibitors in renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11585040-000000000-00000

De novo sirolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma: long-term outcomes and side effects

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11585040-000000000-00000

Conversion to sirolimus with calcineurin inhibitor elimination vs. dose minimization and renal outcome in heart and lung transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11585040-000000000-00000

Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11585040-000000000-00000

Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11585040-000000000-00000

Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11585040-000000000-00000

Early experience with sirolimus in lung transplant recipients with chronic allograft rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11585040-000000000-00000

Study of anemia after late introduction of everolimus in the immunosuppressive treatment of renal transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11585040-000000000-00000

Effects of everolimus monotherapy on hematological parameters and iron homeostasis in de novo liver transplant recipients: preliminary results

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11585040-000000000-00000

Critical role for PI 3-kinase in the control of erythropoietin-induced erythroid progenitor proliferation.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11585040-000000000-00000

S6 kinase 2 potentiates interleukin-3-driven cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11585040-000000000-00000

Inhibition of proliferation but not erythroid differentiation of J2E cells by rapamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11585040-000000000-00000

Marked erythrocyte microcytosis under primary immunosuppression with sirolimus.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11585040-000000000-00000

Sirolimus interferes with iron homeostasis in renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11585040-000000000-00000

Anemia after late introduction of sirolimus may correlate with biochemical evidence of a chronic inflammatory state

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11585040-000000000-00000

Reduction in erythropoietin resistance after conversion from sirolimus to enteric coated mycophenolate sodium

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11585040-000000000-00000

Posttransplant anemia: the role of sirolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11585040-000000000-00000

Effects of rapamycin on accumulation of alpha-, beta- and gamma-globin mRNAs in erythroid precursor cells from beta-thalassaemia patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11585040-000000000-00000

Rapamycin-mediated induction of gamma-globin mRNA accumulation in human erythroid cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11585040-000000000-00000

Everolimus is a potent inducer of erythroid differentiation and gamma-globin gene expression in human erythroid cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11585040-000000000-00000

Anaemia, microcytosis and sirolimus--is iron the missing link?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11585040-000000000-00000

Lack of hepcidin gene expression and severe tissue iron overload in upstream stimulatory factor 2 (USF2) knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11585040-000000000-00000

Iron imports. IV. Hepcidin and regulation of body iron metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11585040-000000000-00000

The iron exporter ferroportin/Slc40a1 is essential for iron homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11585040-000000000-00000

Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11585040-000000000-00000

Molecular control of iron transport

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11585040-000000000-00000

A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11585040-000000000-00000

Suppression of hepcidin during anemia requires erythropoietic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11585040-000000000-00000

Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11585040-000000000-00000

The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11585040-000000000-00000

Dysregulated monocyte iron homeostasis and erythropoietin formation in patients with anemia of chronic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11585040-000000000-00000

Hepcidin, a urinary antimicrobial peptide synthesized in the liver

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11585040-000000000-00000

Pro-hepcidin: expression and cell specific localisation in the liver and its regulation in hereditary haemochromatosis, chronic renal insufficiency, and renal anaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11585040-000000000-00000

Prohepcidin accumulates in renal insufficiency.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11585040-000000000-00000

Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11585040-000000000-00000

Novel urine hepcidin assay by mass spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11585040-000000000-00000

Detection of serum hepcidin in renal failure and inflammation by using ProteinChip System

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11585040-000000000-00000

Quantitation of hepcidin from human and mouse serum using liquid chromatography tandem mass spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11585040-000000000-00000

Quantification of hepcidin-25 in human serum by isotope dilution micro-HPLC-tandem mass spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11585040-000000000-00000

Development of a method for the sensitive and quantitative determination of hepcidin in human serum using LC-MS/MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11585040-000000000-00000

Immunoassay for human serum hepcidin

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11585040-000000000-00000

Hepcidin--a potential novel biomarker for iron status in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11585040-000000000-00000

A novel immunological assay for hepcidin quantification in human serum

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11585040-000000000-00000

Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11585040-000000000-00000

The immunosuppressant rapamycin blocks in vitro responses to hematopoietic cytokines and inhibits recovering but not steady-state hematopoiesis in vivo

21 January 2018

1 reference

12 December 2020

New antitumor substances of natural origin

1 reference

12 December 2020

The side effect profile of sirolimus: a phase I study in quiescent cyclosporine-prednisone-treated renal transplant patients

1 reference

12 December 2020

Rapamycin for immunosuppression in organ allografting.

1 reference

12 December 2020

Inhibition of human erythroid colony-forming units by interferons alpha and beta: differing mechanisms despite shared receptor

1 reference

12 December 2020

Long-term outcome of sirolimus rescue in kidney-pancreas transplantation

1 reference

12 December 2020

Inhibition of the immune response by rapamycin, a new antifungal antibiotic

1 reference

12 December 2020

Immunosuppressive profile of rapamycin.

1 reference

12 December 2020

Incidence of anemia in sirolimus-treated renal transplant recipients: the importance of preserving renal function

1 reference

12 December 2020

De novo use of sirolimus in immunosuppression regimens in kidney and kidney-pancreas transplantation at the University of California, San Francisco

1 reference

12 December 2020

Late introduction of sirolimus induces anemia in renal transplant recipients

1 reference

12 December 2020

10.2165/11585040-000000000-00000

Identifiers

DOI

1 reference

Dimensions Publication ID

26 July 2017

1027638001

0 references

1 reference